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ABSTRACT 
Background: Patient navigation programs were designed to address barriers to 
healthcare among underserved populations in order to reduce delays in cancer 
care delivery. While emerging data suggest modest effects of navigation on 
reducing delays, there is limited understanding of the association between 
barriers to care and clinical outcomes within patient navigation programs. 
Objective: To investigate the impact of barriers on timely diagnostic care in the 
multicenter Patient Navigation Research Program (PNRP). 
Study Design: Secondary analysis of data from the intervention arms of PNRP 
centers that navigated women for abnormal breast or cervical cancer screening 
tests from 2007 to 2010. 
Methods: Analyses were performed separately for breast and cervical subjects.  
The main independent variables were (a) number of unique barriers to care (0, 
1, 2, or 3+) documented during patient navigation encounters and (b) presence 
of socio-legal barriers (yes/no), those social problems related to meeting life’s 
most basic needs that are supported by public policy, regulation, and 
programming and thus potentially remedied through legal advice or advocacy. 
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The outcome of interest was median time to diagnostic resolution, or the interval 
from index screening abnormality to diagnostic resolution, estimated using 
Kaplan-Meier cumulative incidence curves.  Multivariable Cox proportional 
hazards regression with time to diagnostic resolution as the outcome examined 
the impact of barriers, controlling for socio-demographics and stratifying by study 
center. 
Results: Among 2600 breast screening subjects, three-quarters had barriers to 
care (25% 1 barrier, 16% 2 barriers and 34% 3+ barriers).  Among 1387 cervical 
screening subjects, slightly more than half had barriers (31% 1 barrier, 11% 2 
barriers, and 13% 3+ barriers).  Among breast subjects, we found the presence 
of barriers was associated with less timely resolution for any number of barriers 
compared to no barriers. Among cervical subjects, only the presence of 2 or 
more barriers was associated with less timely resolution.  Both socio-legal and 
non socio-legal barriers were associated with delay among breast and cervical 
subjects. 
Conclusions: Navigated women with barriers resolve cancer screening 
abnormalities at a slower rate compared to those with no barriers.  Further 
research is necessary to maximize the impact of patient navigation programs 
nationwide. 
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INTRODUCTION 
Despite remarkable advances in cancer care, underserved populations 
continue to bear an unequal burden of cancer-related illness.  Low-income 
communities suffer higher mortality rates from cancer compared to affluent 
communities,1 and African-Americans have lower stage-specific survival than 
non-Hispanic Whites for the leading causes of cancer death, in particular breast 
cancer.2,3 
These disparities in cancer outcomes have been attributed to delays and 
differences in care at each point in the care continuum.  Recent immigrants and 
the uninsured are less likely to complete cancer screening4 and, despite a higher 
incidence of cervical cancer, Hispanic women have lower rates of Papanicolau 
testing.5,6  African-American and Hispanic women experience longer time until 
follow-up of an abnormal mammogram than White women.7–9  Such delays 
between detection and initiation of treatment of breast cancer have been 
associated with later stage of diagnosis and lower survival.10  Low socioeconomic 
status is also independently associated with advanced stage of diagnosis and 
lower likelihood of receiving guideline-concordant cancer treatment for breast, 
colon, and prostate cancer.11 
Evidence suggests that these delays may be explained by barriers, or 
obstacles, to healthcare disproportionately faced by low-income and racial 
minority patients that impede timely receipt of healthcare services.  Barriers 
include patient factors such as cancer fatalism,12 fear about a cancer diagnosis 
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or pain from a diagnostic procedures,13–15 lack of understanding of cancer or the 
screening test,12,16 and competing priorities like childcare12,15 and employment.17  
Provider factors include inadequate communication14 and language discordance 
between provider and patient,18,19 and healthcare system factors include health 
insurance8,20,21, location of care,13,20 and scheduling challenges.22 
 Patient navigation has emerged as one partial solution to disparities in 
cancer care delivery. Patient navigation for cancer care grew out of the 
pioneering work of Dr. Harold Freeman, who created the first navigation program 
in 1990 for low-income Black and Hispanic women in Harlem, New York.23  After 
instituting a system to help overcome barriers to breast cancer screening and 
follow-up care, Freeman and colleagues demonstrated a reduction in late-stage 
breast cancer diagnosis.24   Patient navigation has been defined as “the support 
and guidance offered to persons with abnormal cancer screening or a new 
cancer diagnosis in accessing the cancer care system; overcoming barriers; and 
facilitating timely, quality care provided in a culturally sensitive manner”.25  The 
central purpose of patient navigation is the identification and elimination of 
patient-level barriers to care.26   
In 2005, the National Cancer Institute’s (NCI) Center to Reduce Cancer 
Health Disparities, with additional support from the American Cancer Society 
(ACS) and the Avon Foundation, initiated the multicenter Patient Navigation 
Research Program (PNRP) to examine the benefits of patient navigation across 
a diverse population. 25,26 Growing evidence from this scientifically rigorous study 
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has demonstrated the efficacy of patient navigation to decrease the time from an 
abnormal cancer screening test to completion of follow-up testing27–32 and the 
time from diagnosis of cancer to initiation of treatment33,34 in those who receive 
navigation compared to usual care. 
 However, even as patient navigation expands in popularity and 
penetration,35 delays in care still exist within navigation programs.  At some 
centers participating in the PNRP, up to 15% of subjects who had received 
navigation for abnormal breast cancer screening tests still had not completed 
follow-up testing one year after their abnormal mammogram or clinical exam.36  
We hypothesized that these continued delays may be due to different barriers 
faced by navigation recipients.  We therefore aimed to examine the relationship 
between barriers to care identified among women with abnormal cancer 
screening tests and the timeliness of their follow-up testing.  Specifically, we 
examined the relationship between the number of barriers to care and timeliness 
of care, as well as the relationship between the type of barriers to care and 
timeliness of follow-up care.  Better understanding of the association between 
barriers to care and clinical outcomes could inform the design of future navigation 
programs, potentially identifying vulnerable subgroups of subjects within the 
navigation cohort who need additional support and assistance based on their 
barrier profile. 
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BACKGROUND 
The Patient Navigation Research Program 
The PNRP was the first multi-center clinical trial to examine the benefits of 
patient navigation among underserved populations.25 The PNRP compared 
patient navigation with usual care on time to diagnosis or treatment for 
participants with breast, cervical, colorectal, or prostate screening abnormalities 
and/or cancers from ten study centers between 2007 and 2010.  Each of the ten 
PNRP centers recruited participants from between one and 21 local community 
health centers or ambulatory care sites.  Among the participating research 
centers, seven enrolled subjects with abnormal breast cancer screening and four 
enrolled subjects with abnormal cervical cancer screening.  All centers 
participating in the PNRP served patients from underserved or safety-net 
populations in urban or rural communities, particularly those of low 
socioeconomic status and racial/ethnic minorities.  Each center designed and 
implemented navigation in the context of the community setting in which it 
operated, with the expectation of a continuous control group.  
Barriers to Care in the Patient Navigation Research Program 
Based on review of the literature and expert consensus, the PNRP 
investigators developed a list of potential barriers for investigation in the PNRP 
(Table 1).25  Thematically, they may be grouped in various ways, such as barriers 
related to communication (language or interpretation barriers, communication 
concerns with medical personnel), health beliefs (fear, attitudes toward providers, 
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perceptions/beliefs about tests/treatment), or logistic challenges (location of 
health facility, transportation, out of town/country).37 
Table 1: Barriers to care in the Patient Navigation Research Program 
 
Barrier Description 
Socio-Legal Barriers 
Health Insurance Paying for all aspects of health care is a problem 
Financial Problems Dealing with financial problems is interfering with 
receiving health care 
Employment Issues Work demands make getting health care difficult 
Childcare Issues Not having childcare when the patient needs medical care 
Adult Care Difficulty finding support for other family when the patient 
needs medical care 
Housing Worrying about where the patient lives during her health 
care 
Non Socio-Legal Barriers 
System Problems with 
Scheduling Care 
Care provided to patient is not convenient/efficient to 
patient’s needs 
Language/Interpreter Health care personnel and patient do not share a common 
language for communication 
Fear Fear about any aspect of medical care or their health 
Communication Concerns 
with Medical Staff 
Barriers to understanding the information given to a 
patient by medical personnel 
Transportation Difficulty getting from home to where the patient obtains 
her health care 
Social/Practical Support Lacks a person/community to help them through the care 
Perceptions/Beliefs about 
Tests/Treatment 
Personal or cultural beliefs that affect receiving health 
care 
Other Barrier other than one defined in the PNRP framework 
Location of Health Care 
Facility 
Distance from health care facility is a barrier even if 
patient has transportation 
Medical/Mental Health 
Comorbidity 
Medical health problems or mental health problems that 
make getting health care difficult 
Literacy Difficulty understanding written communication from the 
health care setting 
Attitudes toward 
Providers 
Perceptions and beliefs about the health care providers 
that impact receiving care 
Out of town/country Patient known to be out of area during their care 
Patient Disability Disability that makes getting health care difficult 
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In our analysis, we examine barriers using the lens of social determinants 
of health.  Certain unique barriers originate from the conditions and structure of 
society, such as lack of affordable housing, impaired access to education and 
employment, or inadequate income supports, and are the focus of the Medical | 
Legal Partnership (MLP) Boston, a healthcare advocacy program.  The MLP 
model recognizes that many social determinants of health have legal solutions.38  
Legal advocates have the expertise, not found in other members of the 
healthcare team, to identify violations of rights and to take necessary steps to 
hold the appropriate parties accountable.39  
Preliminary studies by our research team suggest that the presence of 
barriers, and in particular, certain socio-legal barriers, contribute to persistent 
delays in care despite navigation.40  We define socio-legal barriers as those 
social problems related to meeting life’s most basic needs that are supported by 
public policy, regulation and programming and thus potentially remedied through 
legal advocacy/action.41  These barriers have a legal dimension to the extent that 
if a patient cannot obtain the necessary support after seeking resources or 
assistance from an agency/authority, then her legal rights may have been 
violated.  These barriers may be especially relevant to socially vulnerable 
individuals in the population.   
Patient navigators may be less well-equipped to enforce prevailing 
regulations on behalf of their patients when such barriers are detected since skill 
and training in legal advocacy were not included in the standard navigator 
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training curriculum.42  Such socio-legal barriers may therefore represent a 
qualitatively distinct class of barriers that exert a different impact on the 
relationship between a patient and her clinical outcome than other barriers. We 
hypothesize that, given the different nature of socio-legal barriers and given the 
limited training that navigators have to address socio-legal barriers, patients with 
one or more socio-legal barriers will experience a longer time to diagnostic 
resolution in spite of navigation.  If indeed socio-legal barriers have a differential 
impact, using this analytic approach could influence and inform future 
organization of navigation and affiliated activities.  For example, navigation 
training may need to be supplemented to equip navigators with the knowledge 
and skills to better address these barriers, or legal advocates or experts in law 
could be added to the navigation care team to meet this unmet need. 
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Conceptual Framework 
The conceptual framework adopted for this analysis was developed by 
investigators at the University of Rochester, one of the research centers 
participating in the PNRP (Figure 1).43  The framework describes patient, 
provider, and system factors that impact the process of care, such as patient 
adherence, and ultimately healthcare outcomes, such as mortality and quality of 
life, for patients in need of cancer care.  Patient access barriers are influenced by 
patient characteristics and in turn affect providers and the healthcare system.  
Patient navigation can intervene in this model by modifying the effects of patient 
access barriers as well as the healthcare system. 
The model was originally described for patients with cancer who are 
pursuing cancer treatment, but it applies to individuals across the cancer care 
spectrum. We have adapted the components within the model to be more 
relevant to subjects with abnormal cancer screening, as in our study.  For 
example, under System Factors, we omitted “cancer treatment protocols” but 
included “protocols for following up abnormal cancer screening”.  We have also 
differentiated patient access barriers as socio-legal barriers or non socio-legal 
barriers to emphasize the differential impact these barriers are theorized to have.  
In our analysis, we hypothesize that timeliness of follow-up care will vary by both 
the number and type of barriers to care even in the presence of patient 
navigation due to the unique nature of socio-legal barriers and the burden of an 
increasing number of barriers.  
	  9 
Figure 1: Conceptual Model of Patient Navigation Impacting Cancer Care Outcomes 
	  	  
Adopted from Hendren et al. 2011	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METHODS 
Design Overview 
We conducted a secondary analysis of data from the intervention arm of 
the PNRP, the first multicenter study of patient navigation for cancer care that 
utilized rigorous scientific methods while applying principles of community-based 
participatory research.25  Our analysis focused on subjects who were navigated 
for abnormal breast and cervical cancer screening tests.  We examined the 
relationship between the number and types of barriers to care identified by 
patient navigators and time to diagnostic follow-up of abnormal cancer screening. 
Barrier information was only collected on subjects who received navigation, 
therefore this analysis is restricted to navigated patients and does not include 
non-navigated control subjects.  All PNRP centers received approvals from their 
local Institutional Review Boards for their study designs.25 
Specific Aims and Hypotheses 
 Our first specific aim was to examine the relationship between the number 
of barriers to care and timeliness of care.  We hypothesized that subjects with 
one or more barriers to care would have longer time to diagnostic resolution of 
abnormal breast and cervical cancer screening tests compared to subjects with 
no barriers to care, and that as the number of barriers identified for a subject 
increased, the time to diagnostic resolution would increase.   
 Our second specific aim was to examine the relationship between the type 
of barriers (socio-legal barriers and non socio-legal barriers) and timeliness of 
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care.  We hypothesized that subjects with at least one socio-legal barrier to care 
would have longer time to diagnostic resolution of abnormal breast and cervical 
cancer screening tests compared to subjects with non socio-legal barriers to care 
or subjects with no barriers to care. 
Patient Navigation Intervention 
 In the PNRP, navigation followed the four-step case management 
model:44 (1) identifying individuals with abnormal cancer screening who may 
need additional support, that is, case identification (2) identifying patient-level 
barriers to completing recommended care (3) developing an individual care plan 
to address barriers and (4) tracking to ensure achievement of the desired 
outcome. 
 To ensure uniform knowledge, skills, and practices, navigators received 
annual, national training designed and delivered by the ACS and the PNRP that 
instructed and evaluated navigators on core competencies of navigation.42  The 
curriculum for the training included an overview of cancer, cancer screening, and 
cancer treatment; the role of patient navigation in reducing cancer disparities; 
identifying and removing barriers to cancer care; communication techniques; 
cultural competency skills; connecting to resources in the community; and the 
ethical conduct of human subjects research.  Navigators also received local 
training at their research sites supplemented by national webinars and underwent 
semiannual on-site competency evaluations by supervisors. 
 All PNRP navigators had at least a high school education or equivalent, 
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were fluent in English, and had basic computer skills.42  While some sites had 
navigators with professional backgrounds (nurses, social workers), most 
employed lay community health workers, health educators, and advocates with 
varying degrees of experience working in healthcare.25  Most navigators were 
female, and many navigators shared cultural or linguistic backgrounds with the 
patients that they served. 
Study Subjects 
For this analysis, eligible subjects included women 18 years of age or 
older enrolled with a breast or cervical cancer screening abnormality.27–32  
Abnormal breast cancer screening included an abnormal clinical breast exam 
concerning for cancer or abnormal imaging such as a screening mammogram, 
ultrasound, or magnetic resonance imaging (MRI) with BIRADS scores of 0, 3, 4, 
or 5 according to the Breast Imaging Reporting and Data System.45  Abnormal 
cervical cancer screening included a clinical examination suspicious for cancer or 
Papanicolaou test results of low grade squamous intraepithelial lesion (LGSIL) or 
high grade squamous intraepithelial lesion (HGSIL), atypical squamous cells of 
undetermined significance (ASCUS) that also tested positive for high-risk human 
papillomavirus (HPV), or atypical glandular cells of undetermined significance 
(AGUS). 
Subjects were excluded if they had cognitive impairment that prevented 
interactions with navigators, had previously received navigation for cancer, or 
had a history of cancer (except for non-melanoma skin cancer) treated within the 
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last five years.  Women were also excluded for pregnancy since the timing and 
management of abnormal screening tests (e.g. cervical biopsy, repeat breast 
imaging) may differ based on pregnancy status. 
Identifying Barriers to Care 
 In order to document the implementation of the patient navigation 
intervention, the PNRP design and analysis committee developed a standard 
navigator log for use by navigators to record their encounters with each enrolled 
subject.  This log included the type of encounter with the patient (e.g. in-person 
at the clinic, by telephone call, etc.), the length of time with the patient during the 
encounter, the total time spent on navigation activities on behalf of the patient 
beyond the direct encounter, barriers to care identified during that encounter, and 
actions taken to address those barriers. 
 As previously stated, the PNRP investigators developed a list of 20 
potential barriers for investigation in the PNRP based on review of the literature 
and expert consensus (Table 1).  With each encounter, the navigator was trained 
to ask open-ended questions and elicit from the subject which of these barriers, if 
any, were operating to affect her receipt of follow-up diagnostic testing.  The 
navigator then documented the barrier or barriers and what actions s/he took in 
response.  If no barriers were found, then the navigator documented “No barriers 
identified”.  Barriers recorded as “Other” were re-categorized into one of the other 
specified barrier types when possible based on accompanying text entered by 
navigators.  The majority could not be re-categorized and were left as “Other/Not 
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Otherwise Specified”.  If subjects had more than one barrier type, then each 
unique barrier was noted in the navigator log. For the purposes of this analysis, if 
a subject had multiple navigation contacts and the same barrier to care was 
noted at subsequent contacts, then that unique barrier was counted only once.  
This decision was made to minimize potential confounding by indication since 
delays in time to resolution could afford more opportunities for encounters and 
therefore more opportunities to identify barriers. 
Data Sources 
The navigator log described above was the source for the number and 
type of barriers.  Socio-demographic information was collected from registration 
data or self-report at the respective research centers.  Clinical data on type and 
dates of tests ordered, tests completed, and test results were manually 
abstracted from electronic health records, physical charts, registration, and 
appointment databases depending on the research center.25 
Study Measures 
Predictor variable: barriers to care 
The predictor variable, barriers to care, was characterized in four different 
ways for our analysis.  First, we categorized subjects dichotomously as those 
with barriers to care identified by navigators and those without barriers to care.  
Second, we categorized subjects according to the number of barriers identified 
by navigators (zero, one, two, or three or more barriers).  We chose to apportion 
the number of barriers in this manner based on the distribution of barriers in our 
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sample.  Using three or more barriers as the final group allowed us to investigate 
the effect of multiple barriers on the outcome of interest without confronting 
diminishing sample sizes as the number of barriers increased. 
Third, we categorized subjects according to the presence or absence of 
socio-legal barriers (SLBs).  As discussed above, SLBs to care are hypothesized 
to represent a different class of obstacles given their origin in the regulations and 
policies of society.  They may therefore require different actions on the part of the 
navigator to address them, such as enlisting legal advice or assistance, and may 
be associated with a longer delay in resolving abnormal screening tests.  The six 
barriers defined as SLBs in our analysis were Insurance, Financial problems, 
Housing, Employment issues, Childcare, and Adult care (Table 1).  These 
barriers reflected the domains served by MLP services and summarized in the 
acronym I-HELP [Income supports and Insurance; Housing and utilities; 
Education and employment; Legal (immigration) status; and Personal and family 
stability and safety].41  
Subjects were classified into one of three categories based on SLBs: (1) 
no barriers to care, (2) non-SLBs to care only (barriers present but none of the 
six SLBs highlighted in our study), and (3) at least one SLB to care (at least one 
of the six SLBs documented at some point in their navigation experience).  We 
posited that the presence of one or more SLBs to care marks a fundamental 
difference in the subject’s trajectory compared to subjects who only have non-
SLBs to care or who have no barriers to care.   
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Lastly, in order to better observe the effect of the number of barriers to 
care among subjects with SLBs or non-SLBs, we divided subjects into five 
categories: (1) no barriers to care, (2) exactly one non-SLB, (3) exactly one SLB, 
(4) two or more non-SLBs, and (5) two or more barriers of which at least one is a 
SLB.  This five-category classification allowed us to compare subjects with 
similar quantity of barriers (e.g. exactly one barrier) but with qualitatively different 
barriers (e.g. exclusively non-SLBs).   
Outcome variable: time to diagnostic resolution 
The outcome variable was time to diagnostic resolution of a screening 
abnormality, defined as a continuous variable as the number of days from the 
index screening abnormality until the date of definitive diagnostic care.  In the 
case of breast screening abnormalities, such diagnostic resolution could be 
immediate follow-up imaging (for BIRADS-0), short interval serial imaging (for 
BIRADS-3), or biopsy (for BIRADS-4 or BIRADS-5).  In the case of cervical 
cancer screening abnormalities, definitive diagnostic testing was usually 
colposcopy.  Time to diagnostic resolution therefore represented a measure of 
timeliness of care. 
Covariates 
Covariates for this analysis included demographic variables that the PNRP 
required all centers to collect, that were informed by our conceptual framework, 
and that have been shown to be associated with delays in completing 
recommended follow-up.43,46  Age at initial abnormal screening was treated as a 
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continuous variable.  Race/ethnicity was coded as White, Black/African-
American, Hispanic/Latina, or Other.  Insurance status was categorized as 
private insurance, public insurance (e.g. Medicaid), or uninsured.  Primary 
language was originally recorded as English, Spanish, or other.  The latter two 
groups were collapsed to create the category of “non-English” to reflect more 
general language distinctions and communication challenges. 
Statistical Analysis 
Analyses were done separately for breast and cervical patients for three 
reasons.  First, the ages at which patients undergo screening for breast and 
cervical cancer differ.  In general, women start screening for cervical cancer at 
age 21 and discontinue screening by age 65.  Breast cancer screening is advised 
to begin at age 40 according to most guidelines47–49 and is recommended 
through age 75.  Most cases of cervical cancer are diagnosed at age 35-44, 
while breast cancer is most often diagnosed at age 55-64.50,51  Second, the 
clinical follow-up time for abnormal test results may differ between breast and 
cervical cancer.  Broadly speaking, cervical cancer is not considered a rapidly-
progressive cancer and thus there may be less urgency to resolve an abnormal 
Papanicolau test compared to an abnormal mammogram.52  Finally, preliminary 
examination of the study data showed that the distribution of barriers was 
different between breast and cervical subjects, supporting the decision to analyze 
the two groups separately.  It was not our aim to compare breast and cervical 
screening subjects, but rather to explore associations of barriers and clinical 
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outcomes in two cancer screening sites for which diagnostic follow-up is 
frequently required and for which navigation has demonstrated benefit. 
For this analysis, we first calculated frequencies of the number of barriers 
to care and the types of barriers to care among all breast and cervical subjects.  
We conducted descriptive statistics to understand the sociodemographic 
characteristics of study subjects with and without barriers to care using analysis 
of variance (ANOVA) for means of continuous variables and chi-square tests for 
categorical variables.   
We conducted unadjusted bivariate analyses to explore associations 
between the number and type of barriers present and the outcome of interest, 
time to diagnostic resolution.  The median number of days to diagnostic 
resolution was estimated using Kaplan-Meier survival curves according to (1) the 
presence or absence of barriers (yes/no) (2) the number of barriers (zero, one, 
two, or three or more) (3) the three-category designation of SLBs (no barriers, 
non-SLBs only, at least one SLB) and (4) the five-category designation of SLBs 
(no barriers to care, exactly one non-SLB, exactly one SLB, two or more non-
SLBs, and two or more barriers of which at least one is a SLB).  Median days to 
resolution were compared using the Kruskall-Wallis test.  
We created several Cox proportional hazards regression models with 
likelihood of diagnostic resolution as the outcome.  The first model included 
number of barriers as the main predictor and did not include a term for SLBs.  
The second model included the three-category SLB variable and did not include 
	  	  19 
the number of barriers.  The third model included the five-category SLB variable, 
which takes into account both the number of barriers and whether the barriers 
are SLB or non-SLBs.  All models were adjusted for continuous age, 
race/ethnicity, insurance, and language, and stratified by research center to 
account for baseline differences among centers.  Adjusted hazard ratio (aHR) 
greater than 1.0 indicates more timely diagnostic resolution compared to the 
reference group.  There was no violation of the proportional hazards assumption. 
To assess the risk of confounding by indication, we calculated the 
proportion of barriers that were identified at the first three encounters to 
determine how many barriers were documented early in navigation.  In a 
sensitivity analysis, the third multivariate model was repeated using only the 
barriers identified at the first encounter.  All analyses were done in Stata version 
10.0, and p<0.05 was used to judge statistical significance. 
Additional Analyses 
We performed several additional analyses to further explore the 
relationship between barriers and outcomes (see Appendix).  We compared the 
sociodemographic characteristics of subjects with different number of barriers 
(zero, one, two, and three or more) and in the three different barrier categories 
(no barriers to care, non-SLB to care only, and at least one SLB to care).  We 
cross-tabulated the distribution of subjects according to the number of barriers 
and the types of barriers in order to better understand the possible correlation of 
barrier number and type. 
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We estimated the median number of days to diagnostic resolution using 
Kaplan-Meier survival curves for each of the 20 defined barrier types in order to 
determine which specific barriers were associated with delay. 
To explore the possible mechanism by which navigation affects resolution 
of screening abnormalities, we examined Navigation Intensity.  Descriptively, 
Navigation Intensity is the degree of effort expended by a navigator on behalf of 
a patient.  Analytically, Navigation Intensity was operationalized using three 
measures of navigator activities that were routinely collected in the navigator logs 
at all centers: (1) the number of minutes that navigators spent on a subject’s 
case (2) the number of encounters between a subject and her navigator and (3) 
the type of encounters documented in the subject’s case (e.g. face-to-face 
encounter with the subject, telephone encounter with the subject, written letters, 
or interacting with healthcare members to facilitate a subject’s care).  These 
three measures were used to create a trichotomous composite variable for 
Navigation Intensity (Low, Moderate, or High).  The percent of subjects who 
received Low, Moderate, and High intensity of navigation was compared 
according to the number of barriers (zero, one, two, or three or more barriers).  
We then repeated this comparison according to the type of barriers (no barriers, 
non-SLBs only, at least one SLB). 
For each of the research centers (seven centers in the case of breast 
screening and four centers in the case of cervical screening), the distribution of 
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the number of barriers and the types of barriers (non-SLB versus SLB) was 
calculated.  Results for these exploratory analyses can be found in the Appendix.  
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RESULTS 
Characteristics of subjects 
 The PNRP recruited subjects from low-income, minority, and underserved 
populations; results are presented separately by cancer screening type.  Table 2 
shows the socio-demographic characteristics of breast screening subjects 
according to the presence of barriers to care.  Nearly three-fourths of subjects 
had one or more barriers to care.  Compared to subjects with no barriers, those 
with barriers were younger (p<0.0002) and more often Hispanic/Latina, 
uninsured, and non-English language speakers (p<0.0001). 
Table 2: Sociodemographic characteristics of women with abnormal breast 
screening, by presence of barriers (N=2600) 
 
Characteristic Total 
N=2600 
No barriers 
N=675 (26%) 
At least one 
barrier 
N=1918 (74%) 
P-value 
Age     
Mean (SD)  48.7 (12.5) 46.7 (12.1) <0.0002 
Race/Ethnicity:    <0.0001 
White 774 53% 22%  
Black/African-
American 
492 22% 18%  
Hispanic/Latina 1163 19% 54%  
Other 170 5% 7%  
Insurance Status:    <0.0001 
Uninsured 1019 16% 48%  
Public 911 37% 35%  
Private 634 46% 17%  
Primary Language:    <0.0001 
English 1481 80% 50%  
Non-English 1079 20% 50%  
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Table 3 shows the socio-demographic characteristics of cervical screening 
subjects according to the presence of barriers to care; 55% had at least one 
barrier to care.  Women with barriers to care were more often Hispanic/Latina, 
uninsured, and non-English language-speaking compared to women with no 
barriers to care (p<0.0001).  Mean age was not significantly different between 
those with barriers and those without barriers. 
Table 3: Sociodemographic characteristics of women with abnormal cervical 
screening, by presence of barriers (N=1387) 
 
Characteristic Total 
N=1387 
No barriers 
N=631 (45%) 
At least one 
barrier 
N=756 (55%) 
P-value 
Age     
Mean (SD)  30.1 (9.9) 31.0 (10.5) 0.1058 
Race/Ethnicity:    <0.0001 
White 241 20% 15%  
Black/African-
American 
437 38% 26%  
Hispanic/Latina 692 40% 58%  
Other 16 1% 1%  
Insurance Status:    <0.0001 
Uninsured 527 28% 47%  
Public 561 46% 37%  
Private 291 27% 17%  
Primary Language:    <0.0001 
English 878 70% 58%  
Non-English 509 30% 42%  
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Barrier prevalence and type 
About one-fourth of breast screening subjects had one barrier to care 
documented during their navigation experience, while 16% had two barriers and 
34% had three or more barriers (Figure 2).  Table 4 displays the frequencies of 
specific barrier types in breast cancer screening subjects.  There were a total of 
6162 barriers identified among 2600 subjects navigated for abnormal breast 
cancer screening.  The most common barriers were Health insurance (27% of 
breast subjects), System problems scheduling care (27%) Language (22%), and 
Fear (20%).  
Less than one-third of cervical screening subjects had exactly one barrier 
to care, while 11% and 13% had two and three or more barriers to care, 
respectively (Figure 3).  There were 1455 barriers identified among 1387 
subjects navigated for abnormal cervical cancer screening.  The most common 
barriers were similar to those among breast subjects: Health insurance (17% of 
cervical subjects), System problems scheduling care (16%), Fear (14%), and 
Language (9%) (Table 4). 
Unadjusted association of barriers and time to diagnostic resolution 
 Table 5 presents the median days to diagnostic resolution according to the 
number and type of barriers among women navigated for abnormal breast cancer 
screening tests.  Compared to women with no barriers to care, women with any 
barriers to care had a significantly longer time to diagnostic resolution (52 days 
compared to 68 days, p=0.0376).  Breast screening subjects with three or more 
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barriers to care resolved a median of 60 days after index screening abnormality, 
an interval that was similar to that of women with no barriers to care (52 days).  
However, women with one barrier to care or two barriers to care resolved a 
median of 83 and 81 days after index screening, respectively (p<0.00001 for 
comparison among groups). 
Table 4: Frequency of barriers to care identified among women with 
abnormal breast and cervical cancer screening tests in the Patient 
Navigation Research Program 
 
Barrier Breast 
N=2600 
Cervical 
N=1387 
 N % N % 
SSB 
Health Insurance 702 27.0 239 17.2 
Financial Problems 358 13.8 40 2.9 
Employment Issues 220 8.5 74 5.3 
Childcare Issues 84 3.2 14 1.0 
Adult Care 61 2.4 5 0.4 
Housing 50 1.9 12 0.9 
Non-SSB 
System Problems with Scheduling Care 695 26.7 215 15.5 
Language/Interpreter 575 22.1 125 9.0 
Fear 512 19.7 199 14.4 
Communication Concerns with Medical Staff 433 16.7 84 6.1 
Transportation 424 16.3 73 5.3 
Social/Practical Support 402 15.5 73 5.3 
Perceptions/Beliefs about Tests/Treatment 355 13.7 86 6.2 
Other 339 13.0 34 2.5 
Location of Health Care Facility 325 12.5 22 1.6 
Medical/Mental Health Comorbidity 224 8.6 63 4.5 
Literacy 204 7.9 30 2.2 
Attitudes toward Providers 72 2.8 14 1.0 
Out of town/country 70 2.7 29 2.1 
Patient Disability 57 2.1 24 1.7 
TOTAL NUMBER OF BARRIERS 6162  1455  
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Figure 2: Distribution of number of barriers among subjects 
with abnormal breast cancer screening (N=2600) 
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Figure 3: Distribution of number of barriers among subjects  
with abnormal cervical cancer screening (N=1387) 
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Table 5: Timeliness of diagnostic resolution among women with abnormal breast 
screening according to presence of barriers, number of barriers, and barrier types 
(N=2600) 
 
 N % Median days to 
diagnostic resolution 
K-M estimate (95% CI) 
P-value 
Any barrier 0.0376 
No 676 26 52 (45, 62)  
Yes 1924 74 68 (62, 75)  
Number of barriers <0.00001 
0 676 26 52 (45, 62)  
1 645 25 83 (65, 104)  
2 403 16 81 (60, 97)  
3+ 876 34 60 (54, 68)  
SLB 3-category <0.00001 
No barriers 676 26 52 (45, 62)  
Non-SLBs only 937 36 87 (75, 103)  
At least 1 SLB 987 38 56 (50, 62)  
SLB 5-category <0.00001 
No barriers 676 26 52 (45, 62)  
1 non-SLB 554 21 94 (72, 126)  
1 SLB 91 4 52 (42, 74)  
2+ non-SLBs only 383 15 84 (69, 102)  
2+ barriers, at least 1 is SLB 896 34 56 (50, 63)  
 
When time to resolution was examined according to the presence of 
SLBs, significant differences again emerged.  Subjects with exclusively non-
SLBs had a longer median interval until diagnostic resolution (87 days) compared 
to subjects with no barriers (52 days) or at least one SLB (56 days) (p<0.00001 
for comparison among the three categories).  This pattern persisted when using 
the five-category classification.  Subjects with exactly one non-SLB or two or 
more non-SLBs had longer time to diagnostic resolution than subjects with at 
least one SLB (p<0.00001 for comparison among the five categories).  Figures 4-
6 show the Kaplan-Meier survival curves for breast cancer screening subjects 
according to number of barriers and type of barriers.	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Figure 4: Kaplan-Meier survival curve: Percent unresolved for breast screening subjects 
by number of barriers 
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Figure 5: Kaplan-Meier survival curve: Percent unresolved for breast screening subjects  
by type of barriers (three-category) 
 
NB: SSB indicates SLB 
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Figure 6: Kaplan-Meier survival curve: Percent unresolved for breast screening subjects 
by type of barriers (five-category) 
 
NB: SSB indicates SLB 
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In the case of cervical cancer screening subjects, the presence of any 
barrier was not associated with a statistically significant difference in time to 
diagnostic resolution compared to the absence of any barriers (Table 6).  Women 
with three or more barriers to care resolved abnormal screening in approximately 
the same amount of time as women with zero or exactly one barrier (69 days for 
three or more barriers compared to 75 days for zero and 71 days for one barrier).  
However, women with two barriers to care had greater delays with a median time 
to resolution of 102 days (p=0.0005 for comparison among groups). 
 
Table 6: Timeliness of diagnostic resolution among women with abnormal 
cervical screening according to presence of barriers, number of barriers, 
and barrier types (N=1387) 
 
 N % Median days to 
diagnostic resolution 
K-M estimate (95% CI) 
P-value 
Any barrier 0.821 
No 631 45 75 (69, 80)  
Yes 756  55 73 (70, 80)  
Number of barriers 0.0005 
0 631 45 75 (69,80)  
1 429 31 71 (68,77)  
2 147 11 102 (84,139)  
3+ 180 13 69 (62,80)  
SLB 3-category 0.0765 
No barriers 631 45 75 (69, 80)  
Non-SLBs only 433 31 73 (69, 85)  
At least 1 SLB 323 23 73 (70, 84  
SLB 5-category 0.0170 
No barriers 631 45 75 (69, 80)  
1 non-SLB 324 23 70 (65, 80)  
1 SLB 105 8 72 (68, 84)  
2+ non-SLBs only 109 8 97 (73, 126)  
2+ barriers, at least 1 is SLB 218 16 74 (66, 91)  	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Figure 7: Kaplan-Meier survival curve: Percent unresolved for cervical screening subjects  
by number of barriers 
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Figure 8: Kaplan-Meier survival curve: Percent unresolved for cervical screening subjects 
by type of barriers (three-category) 
 
 
NB: SSB indicates SLB 
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Figure 9: Kaplan-Meier survival curve: Percent unresolved for cervical screening subjects 
by type of barriers (five-category) 
 
NB: SSB indicates SLB 
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The median days to diagnostic resolution were similar among cervical 
subjects with no barriers, non-SLBs only, and at least one SLB (p=0.0765).  
However, when subjects were classified using the five-category grouping, 
subjects with two or more non-SLBs appeared to have a longer time to diagnostic 
resolution compared to other subjects (97 days, p=0.017).  Figures 7-9 display 
the corresponding Kaplan-Meier survival curves for cervical screening subjects. 
Adjusted association of barriers and time to diagnostic resolution 
Table 7 presents the three Cox proportional hazards regression models 
for breast screening subjects, stratified by research center.  After adjustment for 
race, insurance, language, and age, the presence of any number of barriers was 
associated with less timely resolution compared to no barriers (Model 1).  The 
magnitude of the effect was overall similar regardless of the number of barriers 
(aHR 0.76 for one barrier, 0.69 for two barriers, and 0.74 for three or more 
barriers).  Subjects of Other race were more likely to have timely diagnostic 
resolution compared to White subjects (aHR 1.26, 95% CI 1.005-1.494, 
p=0.044).  Each additional year in age was also associated with a small but 
significant increase in timeliness of resolution. 
In Model 2, non-SLBs and SLBs were associated with significantly less 
timely follow-up care (aHR 0.74 for both).  Using the five-category classification 
of barriers (Model 3), non-SLBs and SLBs of any number were associated with 
less timely follow-up care compared to no barriers with no clear pattern to the 
impact based on type of barrier.  Other race and increasing age were once again 
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associated with more timely diagnostic resolution. 
 Table 8 presents the three stratified regression models for cervical 
screening subjects.  Having either two barriers or three or more barriers was 
significantly associated with less timely resolution in Model 1.  Black/African-
American race (aHR 0.67, 95% CI 0.55-0.81) and public insurance (aHR 0.81, 
95% CI 0.68, 0.95) were associated with less timely resolution.  In contrast, 
subjects whose primary language was not English were more likely to have 
timely resolution compared to English language speakers.  Increasing age was 
also associated with more timely diagnostic resolution. 
Non-SLBs and SLBs were both associated with less timely resolution 
(Model 2), with a slightly greater impact from SLBs [aHR 0.71 (95% CI 0.61, 
0.83) for SLBs versus aHR 0.87 (95% CI 0.76, 0.99) for non-SLBs].  In the five-
category model (Model 3), presence of two or more barriers, whether exclusively 
non-SLBs (aHR 0.75, 95% CI 0.6, 0.94) or including at least one SLB (aHR 0.67, 
95% CI 0.55, 0.8), was associated with delay in achieving diagnostic resolution. 
Sensitivity analyses 
 Approximately 46% of all unique barriers were identified in the first 
encounter among breast screening subjects, with a total of 82.5% of all unique 
barriers identified by the third encounter.  Among cervical screening subjects, 
about 57% of barriers were identified in the first encounter, and 97% of all 
barriers were identified by the third encounter (data not shown). 
 In a sensitivity analysis, Model 3 was repeated using only the barriers 
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identified in the first encounter.  For the breast cancer screening group, the 
adjusted hazard ratios for the association of barriers defined by the five-category 
classification scheme did not change appreciably.  Estimates remained 
statistically significant except in the case of one SLB only, which had the smallest 
number of subjects.  Among cervical cancer screening subjects, the magnitude 
and direction of the adjusted hazard ratios were similar in the model restricted to 
the barriers identified in the first encounter as compared to the original Model 3, 
although two estimates changed in terms of statistical significance given small 
sample sizes for certain groups (data not shown).    
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Table 7: Cox proportional hazards regression models for time to diagnostic resolution among women with 
abnormal breast screening (N=2600) 
Variable Level Model 1: number of 
barriers 
Model 2: SLBs 
(3-category) 
Model 3: SLBs 
(5-category) 
  aHR 95% CI aHR 95% CI aHR 95% CI 
Number of barriers 0 1.0 (ref)    
 1 0.759 0.674, 0.855 
 2 0.692 0.601, 0.796 
 3+ 0.739 0.647, 0.843 
SLBs – 3 category None  1.0 (ref)  
 Non-SLBs only 0.735 0.658, 0.822 
 At least 1 SLB 0.740 0.652, 0.841 
SLBs – 5 category None  1.0 (ref)  
 1 Non-SLB only 0.767 0.678, 0.868 
 1 SLB only 0.709 0.552, 0.910 
 2+ Non-SLBs only 0.687 0.595, 0.794 
 2+ Barriers including 
at least 1 SLB 
0.737 0.646, 0.840 
Race/Ethnicity White 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Black/African-
American 
0.906 0.788, 1.040 0.905 0.788, 1.040 0.904 0.787, 1.038 
 Hispanic/Latina 1.075 0.936, 1.236 1.074 0.935, 1.234 1.080 0.940, 1.241 
 Other 1.226 1.005, 1.494 1.207 0.9915, 1.469 1.238 1.014, 1.510 
Insurance Private 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Uninsured 0.986 0.855, 1.136 0.984 0.854, 1.135 0.982 0.852, 1.132 
 Public 0.952 0.841, 1.077 0.950 0.840, 1.075 0.951 0.841, 1.077 
Language English 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Non-English 0.926 0.818, 1.047 0.923 0.816, 1.044 0.925 0.818, 1.046 
Age Each additional year 1.005 1.001, 1.009 1.005 1.002, 1.009 1.005 1.001, 1.009 	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Table 8: Cox proportional hazards regression models for time to diagnostic resolution among women with 
abnormal cervical cancer screening (N=1387) 
Variable Level Model 1: number of 
barriers 
Model 2: SLBs 
(3-category) 
Model 3: SLBs 
(5-category) 
  aHR 95% CI aHR 95% CI aHR 95% CI 
Number of barriers 0 1.0 (ref)    
 1 0.887 0.777, 1.011 
 2 0.602 0.489, 0.740 
 3+ 0.797 0.661, 0.962 
SLBs – 3 category None  1.0 (ref)  
 Non-SLBs only 0.870 0.762, 0.993 
 At least 1 SLB 0.711 0.607, 0.834 
SLBs – 5 category None  1.0 (ref)  
 1 Non-SLB only 0.912 0.790, 1.053 
 1 SLB only 0.806 0.645, 1.009 
 2+ Non-SLBs only 0.752 0.599, 0.944 
 2+ Barriers including 
at least 1 SLB 
0.665 0.554, 0.798 
Race/Ethnicity White 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Black/African-
American 
0.666 0.549 0.808 0.641 0.529, 0.778 0.650 0.535, 0.789 
 Hispanic/Latina 1.219 0.995, 1.494 1.199 0.978, 1.469 1.212 0.989, 1.485 
 Other 0.708 0.395, 1.268 0.702 0.391, 1.258 0.697 0.389, 1.250 
Insurance Private 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Uninsured 0.928 0.773, 1.113 0.940 0.782, 1.129 0.941 0.784, 1.131 
 Public 0.805 0.683, 0.949 0.796 0.675, 0.938 0.803 0.681, 0.947 
Language English 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Non-English 1.177 1.019, 1.360 1.168 1.012, 1.350 1.169 1.012, 1.350 
Age Each additional year 1.008 1.003, 1.014 1.008 1.004, 1.013 1.008 1.002, 1.013 
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DISCUSSION 
In this secondary analysis of a large, multicenter patient navigation 
program, we found that women with barriers to care experienced delays in follow-
up for abnormal breast or cervical cancer screening tests compared to women 
without barriers.   Among those navigated for breast screening abnormalities, the 
negative effect on timeliness of care was observed regardless of the given 
number of barriers or the type of barrier.  For women with cervical screening 
abnormalities, the impact was most prominent for those with multiple barriers, but 
also did not depend on the type of barrier.   Within a patient navigation program 
for cancer care that has demonstrated the benefits of navigation overall 
compared to usual care,36 barriers were still associated with delays.  These 
findings have important implications for the design and implementation of future 
navigation programs. 
This work is among the few studies that have examined the relationship 
between barriers and clinical outcomes in a patient navigation program, but the 
results of our analyses were unexpected compared to prior work.  We 
hypothesized that, as the number of barriers increased, delays would also 
increase, that is, a possible dose-response relationship would exist similar to one 
observed in comparable analyses performed using data from the Boston PNRP 
site.53  Instead, according to the adjusted model for breast subjects, we found 
that the impact on timeliness of care was relatively similar whether there were 
one, two, or three or more barriers.  In the case of cervical subjects, barriers 
	  42 
significantly affected time to resolution when there were at least two barriers, 
although the aHR estimate for one barrier nearly met statistical significance as 
well (aHR 0.887, 95% CI 0.78, 1.01). 
We further hypothesized that certain barriers, namely SLBs that are based 
in social policies and regulations and that may have legal solutions, would have a 
greater impact on timeliness of care than non-SLBs.  When we categorized 
barriers according to the presence and number of SLBs, our results were also 
unlike earlier investigations.40  In our unadjusted bivariate analyses for breast 
screening subjects, non-SLBs were associated with a greater number of days 
until diagnostic resolution compared to SLBs.  For example, the median number 
of days to diagnostic resolution for breast screening subjects with one non-SLB 
was 94 days versus 52 days for subjects with one SLB.  However, in our 
multivariate model, both non-SLBs and SLBs were associated with statistically 
significant delays.  This relationship was observed in both Model 2, where SLB 
and non-SLBs were considered categorically without accounting for number of 
barriers to care, and Model 3, where type and number of barriers were 
considered simultaneously.  Likewise, among cervical screening subjects, two or 
more non-SLBs were associated with longer time to diagnostic resolution in 
unadjusted analyses (97 days compared to 75 days or less in all other 
categories).  However, both non-SLBs and SLBs were associated with less 
timely resolution in the multivariate model as long as there were at least two 
barriers in total.  
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 Using the same SLB framework and five-category classification, Primeau 
and colleagues in the Boston PNRP found that subjects with multiple barriers 
experienced less timely diagnostic resolution compared to those with no barriers 
or only one barrier, but that subjects with SLBs experienced even greater delays 
than those with a similar number of non-SLBs.40  In our multicenter replication of 
their work, we did not find that the type of barriers had an appreciable differential 
impact on timeliness of care even when accounting for number of barriers.  
These dissimilar findings may be due to the larger sample of subjects with SLBs 
used in our study: 38% of breast and 23% of cervical intervention subjects 
nationally had SLBs compared to only 6% of the intervention subjects in Boston.   
We also combined data from multiple research centers with varied patient 
populations.  These various centers likely had different resources available to 
patients and navigators to address prevalent barriers and different distributions of 
barriers (Appendix Figures G-J).  Whereas health insurance was an uncommon 
barrier in the Boston PNRP due to Massachusetts healthcare reform initiated in 
2006, it was the most frequently identified barrier in both breast and cervical 
subjects across the PNRP centers.  Language/Interpreter barriers may have 
been more commonly identified in research centers that served large patient 
populations with limited English proficiency and magnified the impact of non-
SLBs on the outcome of interest. 
 Barriers to care in the PNRP have also been examined using another 
approach to describe the different kinds of obstacles patients face in their cancer 
	  44 
care journey.  Katz et al. categorized the PNRP barriers based on their 
orientation as “patient focused”, “other focused”, and “system focused”, and 
observed that nearly every category was associated with statistically significant 
delays in resolution in both breast and cervical subjects.54  In other words, using 
this perspective, the particular category of barrier did not appear to be relevant.  
Indeed, Katz and colleagues found that any barriers to care were associated with 
longer time to resolution (aHR 0.74 for breast and 0.79 for cervical) compared to 
no barriers to care.  Our observation that both SLB and non-SLB are negatively 
associated with timeliness of care is consistent with this finding that showed that 
the presence of barriers of any kind is associated with delays. 
While these studies together did not find groupings of barriers to be 
important, individual barriers may have greater impact in delaying care.  When 
specific barriers were tested for their effect on time to resolution, Katz et al found 
that, although categories of barriers did not matter, certain distinct barriers, such 
as Co-morbidity or Out of town/country were associated with delays whereas 
other barriers, such as Perceptions/beliefs about tests and Transportation were 
not (Appendix Tables G, H).  This may indicate that the categorization schemes 
tested to date may not adequately capture what aspects of barriers render them 
especially harmful to clinical outcomes.  Our hypothesis was that SLBs represent 
a class of barriers that may be especially relevant to vulnerable individuals in 
society.  These barriers stem from public policies and regulations surrounding 
rights to housing, income supports, and personal safety, and interventions by 
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legal advocates or social workers may be required to address them.  Navigators 
in fact were not trained to identify barriers within this framework, and may have 
been less proficient in identifying these barriers compared to other barriers, such 
as Fear or Interpreter needs, for which they had ample instruction and 
experience.  The lack of a differential impact of SLBs compared to non-SLBs 
could therefore be explained in part by relative underreporting of SLBs by 
navigators.  
While our framework did not reveal a differential impact on time to follow-
up, another approach might be to consider in general how easily a barrier may be 
remedied.  There is little a navigator can do if a subject is out of town and not 
available to come to an appointment, but a lack of transportation can be more 
simply corrected with travel vouchers.  We attempted to evaluate relative 
navigation need by examining the association of Navigation Intensity and barrier 
number and type (Appendix Tables I-L and Figures C-F).  Higher intensity of 
navigation was associated with a greater number of barriers and with having at 
least one SLB.  This approach is limited, however, by the risk of confounding by 
indication. 
All PNRP research centers recruited subjects from underserved, low-
income, and/or minority communities, and yet even within this already 
disadvantaged population, we found that those with barriers and those with SLBs 
were especially vulnerable.  They were more often uninsured, non-English 
language speaking, Hispanic/Latina, and, in the case of breast subjects, younger.  
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These measurable markers of disadvantage are part of a collection of social risk 
factors including ones not directly measured in this study (e.g. low income, low 
health literacy, low educational attainment).  Such socio-demographic 
characteristics could be used to target navigation services to subjects most likely 
to have barriers and therefore most at risk of experiencing delays.  Hendren and 
colleagues examined barriers to care collected on newly-diagnosed cancer 
patients receiving navigation services and found that minority race/ethnicity was 
associated with greater navigation need, as measured by time spent by 
navigators.43  Together with unemployment, unmarried status, and cancer 
treatment variables, race/ethnicity explained much of the variation in navigation 
need.  The authors suggested using minority status as a tool for directing 
navigation interventions to vulnerable cancer patients.  While this 
recommendation may not be pertinent to all communities, it highlights the 
broader importance of tailoring navigation programs to local needs. 
Notably, nearly three-fourths of breast subjects had at least one barrier to 
care identified while only about half of cervical subjects had any barriers.  In the 
era of accountable care, one could argue that a resource-intense service like 
patient navigation should be directed to those patients who need it most – 
patients with barriers and delays.  On the other hand, in a population where 
barriers are widespread, as they were among the breast subjects, it may be more 
efficient to provide navigation uniformly without attempting to differentiate those 
with barriers from those without barriers.  The more likely scenario, as navigation 
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spreads to more settings and populations, will be that a proportion of patients will 
not have barriers and thus not need navigation.  The challenge for future 
navigation programs will be to effectively identify their target patient population. 
 One of the strengths of this study is that it included subjects who represent 
the most disadvantaged members of the population and therefore the very 
individuals for whom patient navigation is intended.  We improved on the 
generalizability of prior work by including subjects from diverse communities 
across the country, and our large sample size allowed us to examine differences 
between several groups using the five-category SLB classification.  Furthermore, 
barriers in the PNRP were collected prospectively, and navigators received 
standardized training on how to identify and document barriers in a common 
navigator tracking log which allowed us to combine data across centers. 
 Still, we recognize certain limitations in this secondary analysis.  Barrier 
information was not collected on non-navigated control subjects, therefore we 
cannot assess the impact of the navigation intervention on subgroups by number 
or type of barriers.  The various research centers participating in the PNRP 
differed in a number of ways, including their study designs, patient populations, 
and distribution of barriers.  Barrier information was most likely collected 
differently at various research centers in ways that reflect the local burden of 
barriers, availability of resources to address the barriers, and individual 
knowledge and skills of the navigators.  As illustrated in our conceptual 
framework, other factors besides barriers to care can have an impact on 
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timeliness of care.  Provider factors, such as cultural competency, and navigator 
factors, such as personality and racial concordance, also influence patient 
outcomes.55  We attempted to account for differences between research centers 
by stratifying by center in adjusted analyses.  Although we cannot assess fidelity 
of implementation of the navigation intervention, navigators at all PNRP centers 
did receive uniform training and competency evaluation on the identification and 
documentation of barriers in order to standardize their practices.   
We created the novel category of SLBs using the six barriers from the 
PNRP framework that best reflected obstacles for which legal regulations and 
protections exist, however, the original barriers in the PNRP were not defined 
with this classification in mind.  Our approach is therefore exploratory in nature. 
In this analysis, there is a risk of confounding by indication since delays in 
care provide more opportunities for encounters and therefore more opportunities 
to identify barriers.  We sought to minimize this potential risk by only counting 
barriers once even if the same barrier was documented on subsequent 
encounters.  One weakness of this approach is that it does not allow 
investigation of the effect of persistent barriers over time.  Such barriers that are 
repeatedly identified may represent the most challenging ones for navigators to 
address and the most deleterious to clinical outcomes.  Still, we found that the 
majority of barriers were found within the first three encounters, suggesting that a 
limited proportion of barriers were identified with additional encounters.  In a 
sensitivity analysis using only the number of barriers identified at the first 
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encounter, we found that the association between barriers and timeliness of 
follow-up care remained essentially the same, again implying a minimal impact of 
confounding by indication. 
This analysis used data from women needing follow-up for abnormal 
breast and cervical cancer screening, therefore the findings cannot be 
generalized to other cancer screening tests or patients diagnosed with cancer 
and receiving navigation.  While it was not our intention to compare breast and 
cervical subjects, we observed that the distribution and impact of barriers differed 
depending on the cancer site. 
Although we do not know if barriers were eliminated or addressed, 
navigators did document what actions they took after identifying a barrier.  Nearly 
all barriers resulted in some action on the part of the navigator, such as providing 
education or placing a referral.54  Our conceptual framework posits that 
timeliness of care reflects the inherent unfavorable effect of a barrier as well as a 
navigator’s ability to resolve that barrier. 
CONCLUSIONS AND IMPLICATIONS 
 In a multicenter patient navigation program, we found that patients with 
documented barriers to care are among the most vulnerable members of the 
population and that barriers to care, whether SLBs or non-SLBs, are associated 
with less timely follow-up of abnormal breast and cervical cancer screening tests.  
In order to equitably eliminate delays in care, patient navigation programs should 
refine and strengthen processes of recognizing patients who are most likely to 
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have barriers to care and target navigation services accordingly.  The particular 
barriers that are most common and most important will vary by cancer screening 
site and patient population, therefore navigation programs should characterize 
the needs of their local communities in order to optimize the efficiency and 
effectiveness of their interventions.  Future research should collect information on 
barriers in patients not receiving navigation for comparison to navigated patients 
in order to understand the differential benefits of navigation according to barrier 
number and type. 
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APPENDIX 
Appendix Table A shows that, as the number of documented barriers 
increases, markers of social disadvantage become more prominent among 
subjects navigated for abnormal breast cancer screening.  For example, while 
only 32% of subjects with one barrier were uninsured, 62% of subjects with three 
or more barriers were uninsured.  Among cervical subjects, characteristics of 
social vulnerability were also more pronounced, though less dramatically, as the 
number of barriers increased (Appendix Table B). 
Among both breast and cervical screening subjects with at least one SLB, 
a greater proportion were Hispanic/Latina, uninsured, and non-English language 
speaking compared to subjects with non-SLBs or no barriers (Appendix Tables C 
and D).   
Table E and Figure A display the distribution of breast screening subjects 
according to number of SLBs and non-SLBs, and suggest that subjects with 
SLBs have more barriers overall.  For example, among the 603 subjects with 
exactly one SLB, the majority (365) have two or more non-SLBs.  By contrast, 
among the 744 subjects with exactly one non-SLB, most subjects (554) have 
zero SLBs. 
 Table F and Figure B display the corresponding distribution of cervical 
screening subjects, among whom barriers were overall less prevalent.  Still, a 
similar pattern appears again wherein SLBs are associated with more non-SLBs.  
For example, among the 236 subjects with two or more non-SLBs, only 32 (14%) 
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had two or more SLBs.  Conversely, among the 52 subjects with two or more 
SLBs, over half also had two or more non-SLBs. 
Table G presents median days to diagnostic resolution for selected 
specific barriers among breast screening subjects.  Presence of certain barriers 
was associated with marked delays compared to having no barriers.  For 
instance, presence of an Out of Area barrier was associated with a median 
follow-up of nearly five months.  The SLB associated with the longest time to 
diagnostic resolution was Adult Care at 105 days. 
As shown in Table H, among cervical screening subjects, barriers 
associated with noticeable delays included Out of Area, Location of Healthcare 
Facility, and Attitude toward Providers, however, each of these barriers was 
found in less than 3% of subjects.  The SLB associated with the longest time to 
diagnostic resolution was Housing at 143 days, which was identified in only 12 
subjects. 
Table I and Figure C display the association of Navigation Intensity (Low, 
Moderate, and High) and number of barriers.  As the number of barriers 
increases, a greater proportion of subjects receive Moderate or High intensity of 
navigation.  A similar association is observed among cervical subjects (Table J 
and Figure D). 
Table K and Figure E present the association of navigation intensity and 
type of barrier (no barrier, non-SLBs only, at least one SLB).  Nearly all subjects 
with at least one SLB received Moderate or High intensity of navigation, while 
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approximately half of subjects with exclusively non-SLB received a similar level 
of intensity of navigation.  Table L and Figure F display the corresponding 
distribution for cervical subjects, where once again presence of at least one SLB 
is associated with greater intensity of navigation compared to only non-SLBs. 
Figure G demonstrates the variability in the distribution of number of 
barriers by research centers that navigated women with abnormal breast cancer 
screening.  Boston and Ohio had the greatest proportion of subjects with no 
barriers (41% and 57%, respectively), while Chicago, San Antonio, and Tampa 
had the greatest proportion of enrolled subjects with three or more barriers (49%, 
67%, and 74%, respectively). 
As shown in Figure H, the distribution of barriers among research centers 
that navigated women for abnormal cervical cancer screening was more 
comparable, though Boston and Ohio once again had the largest proportion with 
no barriers (55% and 44%, respectively). 
Figure I shows that, among breast screening subjects, the majority of 
subjects with SLBs originated from the Tampa while most subjects with non-
SLBs came from Boston.  Among cervical screening subjects, the San Antonio 
research center contributed the majority of those with SLBs and Boston again 
contributed most subjects with no barriers or non-SLBs. 
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Table A: Sociodemographic characteristics of women with abnormal breast 
screening, by number of barriers (N=2600) 
 
Characteristic No barriers 
N=675 
(26%) 
1 barrier 
N=645 
(25%) 
2 barriers 
N=403 
(15%) 
3+ barriers 
N=876 
(34%) 
P-value 
Age:    
Mean (SD) 48.7 (12.5) 48.5 (12) 47.1 (11.2) 45.2 (12.4) <0.00001 
Race/Ethnicity:   <0.0001 
White 359 (53%) 221 (34%) 77 (19%) 117 (13%)  
Black/African-
American 
151 (22%) 163 (25%) 72 (18%) 106 (12%)  
Hispanic/Latina 130 (19%) 221 (34%) 195 (48%) 617 (71%)  
Other 36 (5%) 40 (6%) 59 (15%) 35 (4%)  
Insurance Status:   <0.0001 
Private 309 (46%) 188 (29%) 74 (19%) 63 (7%)  
Uninsured 110 (16%) 203 (32%) 174 (44%) 532 (62%)  
Public 250 (37%) 249 (39%) 145 (37%) 267 (31%)  
Primary Language:   <0.0001 
English 539 (80%) 403 (64%) 191 (48%) 348 (40%)  
Non-English 132 (20%) 225 (36%) 208 (52%) 514 (60%)  
 
Table B: Sociodemographic characteristics of women with abnormal 
cervical screening, by number of barriers (N=1387) 
 
Characteristic No Barriers 
N=631 (45%) 
1 barrier 
N=429 (31%) 
2 barriers 
N=147 
(11%) 
3+ barriers 
N=180 
(13%) 
P-value 
Age:    
Mean (SD) 30.1 (9.9) 30.1 (10.0) 31.8 (11.5) 32.2 (10.5) 0.0248 
Race/Ethnicity:   <0.0001 
White 129 (20%) 69 (16%) 17 (12%) 26 (14%)  
Black/African-
American 239 (38%) 112 (26%) 53 (36%) 
33 (18%)  
Hispanic/Latina 254 (40%) 243 (57%) 75 (51%) 120 (67%)  
Other 9 (1%) 5 (1%) 1 (1%) 1 (1%)  
Insurance Status:   <0.0001 
Private 167 (27%) 80 (19%) 22 (15%) 22 (12%)  
Uninsured 175 (28%) 190 (45%) 66 (46%) 96 (54%)  
Public 286 (46%) 157 (37%) 57 (39%) 61 (34%)  
Primary Language:   <0.0001 
English 443 (70%) 245 (57%) 85 (58%) 105 (58%)  
Non-English 188 (30%) 184 (43%) 62 (42%) 75 (42%)  
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Table C: Sociodemographic characteristics of women with abnormal breast 
screening, by type of barriers (N=2600) 
 
 No barriers 
N=675 (26%) 
Non-SLB only 
N=937 (36%) 
At least one SLB 
N=986 (38%) 
P-value 
Age:   
Mean (SD) 48.7 (10.2) 49.2 (12.0) 44.4 (11.7) <0.0001 
Race/Ethnicity:  <0.0001 
White 359 (53%) 263 (28%) 152 (15%)  
Black/African-American 151 (22%) 193 (21%) 148 (15%)  
Hispanic/Latina 130 (19%) 371 (40%) 662 (67%)  
Other 36 (5%) 110 (12%) 24 (2%)  
Insurance Status:  <0.0001 
Private 309 (46%) 232 (25%) 93 (10%)  
Uninsured 110 (16%) 275 (30%) 634 (66%)  
Public 250 (37%) 420 (45%) 241 (25%)  
Primary Language:  <0.0001 
English 539 (80%) 519 (56%) 423 (44%)  
Non-English 132 (20%) 401 (44%) 546 (56%)  
 
Table D: Sociodemographic characteristics of women with abnormal 
cervical screening, by type of barriers (N=1387) 
 
Characteristic No Barriers 
N=631 (45%) 
Non-SLB only 
N=433 (31%) 
At least one SLB 
N=322 (23%) 
P-value 
Age:   
Mean (SD) 30.1 (9.9) 31.3 (11.1) 30.4 (9.5) 0.138 
Race/Ethnicity:  <0.0001 
White 129 (20%) 70 (16%) 42 (13%)  
Black/African-
American 239 (38%) 140 (32%) 58 (18%) 
 
Hispanic/Latina 254 (40%) 217 (50%) 221 (69%)  
Other 9 (1%) 6 (1%) 1 (0%)  
Insurance Status:  <0.0001 
Private 167 (27%) 92 (21%) 32 (10%)  
Uninsured 175 (28%) 147 (34%) 205 (64%)  
Public 286 (46%) 192 (45%) 83 (26%)  
Primary Language:  <0.0001 
English 443 (70%) 264 (61%) 171 (53%)  
Non-English 188 (30%) 169 (39%) 152 (47%)  
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Table E: Distribution of subjects according to type and number of barriers 
among breast screening subjects 
 
 Number of non-SLBs TOTAL 
Number of 
SLBs 
None 1 2 or more  
None 676 554 383 1613 
1 91 147 365 603 
2 or more 22 43 319 384 
TOTAL 789 744 1067 2600 
 
 
Figure A: Distribution of subjects according to type and number of barriers 
among breast screening subjects 
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Table F:  Distribution of subjects according to type and number of barriers 
among cervical screening subjects 
 
 Number of non-SLBs TOTAL 
Number of 
SLBs 
None 1 2 or more  
None 631 324 109 1064 
1 105 71 95 271 
2 or more 9 11 32 52 
TOTAL 745 406 236 1387 
 
 
Figure B: Distribution of subjects according to type and number of barriers 
among cervical screening subjects 
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Table G: Timeliness of diagnostic resolution among women with abnormal 
breast screening according to according to selected specific barriers 
(N=2600) 
Barrier N % Median days to diagnostic 
resolution 
K-M estimate (95% CI) 
No barriers 676 26 52 (45, 62) 
Barrier NOS 271 10 183 (91, 204) 
Out of area 70 3 154 (81, 258) 
Adult care 61 2 105 (63, 174) 
Language 575 22 75 (63, 83) 
Perceptions 355 14 70 (54, 80) 
Transportation 424 16 68 (55, 76) 
 
Table H: Timeliness of diagnostic resolution among women with abnormal 
cervical screening according to according to selected specific barriers 
(N=1387) 
 
Barrier N % Median days to diagnostic 
resolution 
K-M estimate (95% CI) 
No barriers 631 45 75 (69, 80) 
Out of area 29 2 179 (91, 358) 
Barrier NOS 34 3 176 (118, 268) 
Location 22 2 146 (55, 261) 
Attitude 14 1 144 (49, 301) 
Co-morbidities 63 5 143 (87, 222) 
Housing 12 1 143 (56, 365) 
Communication 84 6 90 (71, 119) 
System problems 215 16 86 (73, 112) 
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Table I: Association of navigation intensity and number of barriers among 
subjects with abnormal breast screening (N=2592) 
 
 Intensity of navigation TOTAL 
Number of 
unique 
barriers 
Low Moderate High  
0 504 (75.45) 133 (19.91) 31 (4.64) 668 
1 347 (53.80) 232 (35.97) 66 (10.23) 645 
2 98 (24.32) 192 (47.64) 113 (28.04) 403 
3+ 24 (2.74) 208 (23.74) 644 (73.52) 876 
TOTAL 973 (37.54) 765 (29.51) 854 (32.95) 2592 
 
Figure C: Association of navigation intensity and number of barriers 
among subjects with abnormal breast screening (N=2592) 
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Table J: Association of navigation intensity and number of barriers among 
subjects with abnormal cervical screening (N=1384) 
 Intensity of navigation TOTAL 
Number of 
unique 
barriers 
Low Moderate High  
0 390 (62.10) 229 (36.46) 9 (1.43) 628 
1 211 (49.18) 187 (43.59) 31 (7.23) 429 
2 27 (18.37) 82 (55.78) 38 (25.85) 147 
3+ 6 (3.33) 84 (46.67) 90 (50.00) 180 
TOTAL 634 (45.81) 582 (42.05) 168 (12.14) 1384 
 
Figure D: Association of navigation intensity and number of barriers 
among subjects with abnormal cervical screening (N=1384) 
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Table K: Association of navigation intensity and type of barriers among 
subjects with abnormal breast screening (N=2592) 
 
 Intensity of navigation TOTAL 
SLB category Low Moderate High  
No barriers 504 (75.45) 133 (19.91) 31 (4.64) 668 
Non-SLB barriers 
only 
416 (44.40) 350 (37.35) 171 (18.25) 937 
At least 1 SLB 53 (5.37) 282 (28.57) 652 (66.06) 987 
TOTAL 973 (37.54) 765 (29.51) 854 (32.95) 2592 
 
 
Figure E: Association of navigation intensity and type of barriers among 
subjects with abnormal breast screening (N=2592) 
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Table L: Association of navigation intensity and number of barriers among 
subjects with abnormal cervical screening (N=1384) 
 
 Intensity of navigation TOTAL 
SLB category Low Moderate High  
No barriers 390 (62.10) 229 (36.46) 9 (1.43) 628 
Non-SLB barriers 
only 
207 (47.81) 181 (41.80) 45 (10.39) 433 
At least 1 SLB 37 (11.46) 172 (53.25) 114 (35.29) 323 
TOTAL 634 (45.81) 582 (42.05) 168 (12.14) 1384 
 
 
Figure F: Association of navigation intensity and number of barriers among 
subjects with abnormal cervical screening (N=1384) 
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Figure G: Distribution of number of barriers according to research center among subjects  
with abnormal breast screening (N=2600) 
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Figure H: Distribution of number of barriers according to research center among subjects  
with abnormal cervical screening (N=1387) 
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Figure I: Distribution of type of barriers according to research center among subjects  
with abnormal breast screening (N=2600) 
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Figure J: Distribution of type of barriers according to research center among subjects  
with abnormal cervical screening (N=1387) 
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